BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31874896)

  • 1. Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study.
    Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
    BMJ Open; 2019 Dec; 9(12):e033944. PubMed ID: 31874896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study.
    Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
    Eur Urol Oncol; 2018 May; 1(1):37-45. PubMed ID: 31100227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choosing active surveillance versus curative treatment in a population-based survey of men with low-risk prostate cancer.
    Xu J; Janisse J; Goodman M
    Ann Fam Med; 2022 Apr; 20(20 Suppl 1):. PubMed ID: 36696653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer.
    Ciccone G; De Luca S; Oderda M; Munoz F; Krengli M; Allis S; Baima CG; Barale M; Bartoncini S; Beldì D; Bellei L; Bellissimo AR; Bernardi D; Biamino G; Billia M; Borsa R; Cante D; Castelli E; Cattaneo G; Centrella D; Collura D; Coppola P; Dalmasso E; Di Stasio A; Fasolis G; Fiorio M; Garibaldi E; Girelli G; Griffa D; Guercio S; Migliari R; Molinaro L; Montefiore F; Montefusco G; Moroni M; Muto G; Ponti di Sant'Angelo F; Ruggiero L; Ruo Redda MG; Serao A; Squeo MS; Stancati S; Surleti D; Varvello F; Volpe A; Zaramella S; Zarrelli G; Zitella A; Bollito E; Gontero P; Porpiglia F; Galassi C; Bertetto O;
    JAMA Netw Open; 2023 Oct; 6(10):e2338039. PubMed ID: 37847502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer.
    Olsson H; Nordström T; Clements M; Grönberg H; Lantz AW; Eklund M
    Eur Urol Oncol; 2020 Oct; 3(5):640-647. PubMed ID: 31235395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
    Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
    Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
    Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
    Maurice MJ; Zhu H; Kiechle JE; Kim SP; Abouassaly R
    J Urol; 2016 Apr; 195(4 Pt 1):919-24. PubMed ID: 26519653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden.
    Ventimiglia E; Bill-Axelson A; Bratt O; Montorsi F; Stattin P; Garmo H
    JAMA Netw Open; 2022 Sep; 5(9):e2231015. PubMed ID: 36103180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
    Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
    Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
    Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
    BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria.
    Evans MA; Millar JL; Earnest A; Frydenberg M; Davis ID; Murphy DG; Kearns PA; Evans SM
    Med J Aust; 2018 Jun; 208(10):439-443. PubMed ID: 29793403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
    Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
    Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden.
    Nugin H; Folkvaljon Y; Damber JE; Adolfsson J; Robinson D; Stattin P
    Scand J Urol; 2018 Aug; 52(4):277-284. PubMed ID: 30362868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.